Team FiNDeR (Foundation for Neglected Disease Research) has won the Longitude Prize Discovery Award in November 2016 for its project “Biomarker based diagnostics to differentiate between bacterial and viral infections” at an award ceremony held at the Royal Society in London. The award will help develop a rapid point of care diagnostic that will help solve the global antibiotic resistance problem.
FNDR has been awarded a grant for the Development of PM181108 as an anti-tubercular agent by the Biotechnology Industry Research Assistance Council under the CRS scheme. The objectives of this 3 year project are to scale-up the PM181108, conduct pre-clinical DMPK and in vitro clinical isolates studies & develop an oral formulation, to evaluate effect of PM181108 in combination studies in vitro & in vivo and to perform advanced in vivo studies, safety pharmacology & toxicology studies.
FNDR is a part of a consortium which has been awarded a grant for the project “Genomics-driven Dissection of Susceptibility and Drug Resistance to Pulmonary Tuberculosis, with a Geographical Focus on NER” by the Department of Biotechnology under “MDR-TB in North East India: A Genomic Driven Approach -2016-17” program, in July 2017.
FNDR has been awarded a grant by Biotechnology Industry Research Assistance Council (BIRAC), Government of India for its project “Saracatinib, an adjunct therapy candidate for tuberculosis” under its PACE scheme in 2017. FNDR plans to develop the drug in collaboration with International Centre For Genetic Engineering And Biotechnology (ICGEB), New Delhi.